Trial Profile
Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor: A Proof of Principle Trial
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Pasireotide (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 05 Apr 2017 Results (n=8) presented at the 108th Annual Meeting of the American Association for Cancer Research
- 17 Jun 2011 New trial record